Cargando…

Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients

AIM: Advanced liver fibrosis is independently associated with new onset of atrial fibrillation (AF). Non-invasive liver fibrosis scores are considered an effective strategy for assessing liver fibrosis. This study aimed to investigate the association between advanced liver fibrosis and AF recurrence...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhe, Wang, Yijia, Luo, Fangyuan, Zhai, Yafei, Li, Jiaju, Chen, Yinong, Li, Qing, Zhu, Longyang, Jiao, Siqi, Liu, Peng, Zhou, Yifeng, Chen, Yingwei, Dong, Jianzeng, Sun, Yihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583404/
https://www.ncbi.nlm.nih.gov/pubmed/36277780
http://dx.doi.org/10.3389/fcvm.2022.960259
_version_ 1784813067205345280
author Wang, Zhe
Wang, Yijia
Luo, Fangyuan
Zhai, Yafei
Li, Jiaju
Chen, Yinong
Li, Qing
Zhu, Longyang
Jiao, Siqi
Liu, Peng
Zhou, Yifeng
Chen, Yingwei
Dong, Jianzeng
Sun, Yihong
author_facet Wang, Zhe
Wang, Yijia
Luo, Fangyuan
Zhai, Yafei
Li, Jiaju
Chen, Yinong
Li, Qing
Zhu, Longyang
Jiao, Siqi
Liu, Peng
Zhou, Yifeng
Chen, Yingwei
Dong, Jianzeng
Sun, Yihong
author_sort Wang, Zhe
collection PubMed
description AIM: Advanced liver fibrosis is independently associated with new onset of atrial fibrillation (AF). Non-invasive liver fibrosis scores are considered an effective strategy for assessing liver fibrosis. This study aimed to investigate the association between advanced liver fibrosis and AF recurrence after ablation in patients with non-alcoholic fatty liver disease (NAFLD). MATERIALS AND METHODS: A total of 345 AF patients with NAFLD who underwent de novo ablation between 2019 and 2020 at two large hospitals in China were included in this study. AF recurrence was defined as the occurrence of atrial arrhythmia for more than 30 s by electrocardiogram or 24 h Holter monitoring after the first 3 months of ablation. Predictive values of non-alcoholic fatty liver disease fibrosis score (NFS) and Fibrosis-4 (FIB-4) scores for AF burden and recurrence after ablation were assessed. RESULTS: At the 1 year follow-up after ablation, 38.8% of patients showed recurrence. Patients with recurrence who had higher FIB-4 and NFS scores were more likely to have persistent AF and a duration of AF ≥ 3 years. In Kaplan–Meier analysis, patients with intermediate and high NFS and FIB-4 risk categories had a higher risk of AF recurrence. Compared to patients with the low risk, intermediate and high NFS, and FIB-4 risk were independently associated with AF recurrence in multivariate Cox regression analysis (high risk: NFS, hazard ratio (HR): 3.11, 95% confidence interval (CI): 1.68∼5.76, p < 0.001; FIB-4, HR: 3.91, 95% CI: 2.19∼6.98, p < 0.001; intermediate risk: NFS, HR: 1.85, 95% CI: 1.10∼3.10, p = 0.020; FIB-4, HR: 2.08, 95% CI: 1.27∼3.41, p = 0.003). CONCLUSION: NFS and FIB-4 scores for advanced liver fibrosis are associated with AF burden. Advanced liver fibrosis is independently associated with AF recurrence following ablation. Advanced liver fibrosis might be meaningful in risk classification for patients after AF ablation.
format Online
Article
Text
id pubmed-9583404
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95834042022-10-21 Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients Wang, Zhe Wang, Yijia Luo, Fangyuan Zhai, Yafei Li, Jiaju Chen, Yinong Li, Qing Zhu, Longyang Jiao, Siqi Liu, Peng Zhou, Yifeng Chen, Yingwei Dong, Jianzeng Sun, Yihong Front Cardiovasc Med Cardiovascular Medicine AIM: Advanced liver fibrosis is independently associated with new onset of atrial fibrillation (AF). Non-invasive liver fibrosis scores are considered an effective strategy for assessing liver fibrosis. This study aimed to investigate the association between advanced liver fibrosis and AF recurrence after ablation in patients with non-alcoholic fatty liver disease (NAFLD). MATERIALS AND METHODS: A total of 345 AF patients with NAFLD who underwent de novo ablation between 2019 and 2020 at two large hospitals in China were included in this study. AF recurrence was defined as the occurrence of atrial arrhythmia for more than 30 s by electrocardiogram or 24 h Holter monitoring after the first 3 months of ablation. Predictive values of non-alcoholic fatty liver disease fibrosis score (NFS) and Fibrosis-4 (FIB-4) scores for AF burden and recurrence after ablation were assessed. RESULTS: At the 1 year follow-up after ablation, 38.8% of patients showed recurrence. Patients with recurrence who had higher FIB-4 and NFS scores were more likely to have persistent AF and a duration of AF ≥ 3 years. In Kaplan–Meier analysis, patients with intermediate and high NFS and FIB-4 risk categories had a higher risk of AF recurrence. Compared to patients with the low risk, intermediate and high NFS, and FIB-4 risk were independently associated with AF recurrence in multivariate Cox regression analysis (high risk: NFS, hazard ratio (HR): 3.11, 95% confidence interval (CI): 1.68∼5.76, p < 0.001; FIB-4, HR: 3.91, 95% CI: 2.19∼6.98, p < 0.001; intermediate risk: NFS, HR: 1.85, 95% CI: 1.10∼3.10, p = 0.020; FIB-4, HR: 2.08, 95% CI: 1.27∼3.41, p = 0.003). CONCLUSION: NFS and FIB-4 scores for advanced liver fibrosis are associated with AF burden. Advanced liver fibrosis is independently associated with AF recurrence following ablation. Advanced liver fibrosis might be meaningful in risk classification for patients after AF ablation. Frontiers Media S.A. 2022-10-06 /pmc/articles/PMC9583404/ /pubmed/36277780 http://dx.doi.org/10.3389/fcvm.2022.960259 Text en Copyright © 2022 Wang, Wang, Luo, Zhai, Li, Chen, Li, Zhu, Jiao, Liu, Zhou, Chen, Dong and Sun. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Wang, Zhe
Wang, Yijia
Luo, Fangyuan
Zhai, Yafei
Li, Jiaju
Chen, Yinong
Li, Qing
Zhu, Longyang
Jiao, Siqi
Liu, Peng
Zhou, Yifeng
Chen, Yingwei
Dong, Jianzeng
Sun, Yihong
Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients
title Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients
title_full Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients
title_fullStr Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients
title_full_unstemmed Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients
title_short Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients
title_sort impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9583404/
https://www.ncbi.nlm.nih.gov/pubmed/36277780
http://dx.doi.org/10.3389/fcvm.2022.960259
work_keys_str_mv AT wangzhe impactofadvancedliverfibrosisonatrialfibrillationrecurrenceafterablationinnonalcoholicfattyliverdiseasepatients
AT wangyijia impactofadvancedliverfibrosisonatrialfibrillationrecurrenceafterablationinnonalcoholicfattyliverdiseasepatients
AT luofangyuan impactofadvancedliverfibrosisonatrialfibrillationrecurrenceafterablationinnonalcoholicfattyliverdiseasepatients
AT zhaiyafei impactofadvancedliverfibrosisonatrialfibrillationrecurrenceafterablationinnonalcoholicfattyliverdiseasepatients
AT lijiaju impactofadvancedliverfibrosisonatrialfibrillationrecurrenceafterablationinnonalcoholicfattyliverdiseasepatients
AT chenyinong impactofadvancedliverfibrosisonatrialfibrillationrecurrenceafterablationinnonalcoholicfattyliverdiseasepatients
AT liqing impactofadvancedliverfibrosisonatrialfibrillationrecurrenceafterablationinnonalcoholicfattyliverdiseasepatients
AT zhulongyang impactofadvancedliverfibrosisonatrialfibrillationrecurrenceafterablationinnonalcoholicfattyliverdiseasepatients
AT jiaosiqi impactofadvancedliverfibrosisonatrialfibrillationrecurrenceafterablationinnonalcoholicfattyliverdiseasepatients
AT liupeng impactofadvancedliverfibrosisonatrialfibrillationrecurrenceafterablationinnonalcoholicfattyliverdiseasepatients
AT zhouyifeng impactofadvancedliverfibrosisonatrialfibrillationrecurrenceafterablationinnonalcoholicfattyliverdiseasepatients
AT chenyingwei impactofadvancedliverfibrosisonatrialfibrillationrecurrenceafterablationinnonalcoholicfattyliverdiseasepatients
AT dongjianzeng impactofadvancedliverfibrosisonatrialfibrillationrecurrenceafterablationinnonalcoholicfattyliverdiseasepatients
AT sunyihong impactofadvancedliverfibrosisonatrialfibrillationrecurrenceafterablationinnonalcoholicfattyliverdiseasepatients